Thomas P Oreilly - Insider Trading Tracker

Introduction

This page provides a comprehensive analysis of the known insider trading history of Thomas P Oreilly. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

Companies with Reported Insider Positions

The SEC filings indicate Thomas P Oreilly has reported holdings or trades in the following companies:

How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Thomas P Oreilly. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases NHS RT / Neuberger Berman High Yield Strategies Fund Inc. - Equity Right - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in NHS RT / Neuberger Berman High Yield Strategies Fund Inc. - Equity Right. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
2015-10-08	NHS	OREILLY THOMAS P	14,543	10.4203	14,543	10.4203	151,542	336	11.9400	22,101	14.58
2015-10-08	NHS	OREILLY THOMAS P	14,543	10.4203	14,543	10.4203	151,542
2015-10-07	NHS	OREILLY THOMAS P	5,457	10.2956	5,457	10.2956	56,183
2015-10-07	NHS	OREILLY THOMAS P	5,457	10.2956	5,457	10.2956	56,183
2015-07-14	NHS	OREILLY THOMAS P	5,000	11.5456	5,000	11.5456	57,728
2015-07-13	NHS	OREILLY THOMAS P	4,502	11.5740	4,502	11.5740	52,106
2013-09-19	NHS	OREILLY THOMAS P	10,000	13.1101	10,000	13.1101	131,101
2013-07-17	NHS	OREILLY THOMAS P	8,000	13.0012	8,000	13.0012	104,010
2013-06-06	NHS	OREILLY THOMAS P	10,000	13.3522	10,000	13.3522	133,522
2012-11-19	NHS	OREILLY THOMAS P	3,120	13.0100	3,120	13.0100	40,591
2012-11-15	NHS	OREILLY THOMAS P	3,120	13.0131	3,120	13.0131	40,601
2012-11-15	NHS	OREILLY THOMAS P	3,120	13.0131	3,120	13.0131	40,601

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Sales NHS RT / Neuberger Berman High Yield Strategies Fund Inc. - Equity Right - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in NHS RT / Neuberger Berman High Yield Strategies Fund Inc. - Equity Right. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Min	Price at Min	Max Loss Avoided ($)	Max Loss Avoided (%)
2017-08-10	NHS	OREILLY THOMAS P	4,000	11.8296	4,000	11.8296	47,318	326	10.7900	-4,158	-8.79
2017-08-09	NHS	OREILLY THOMAS P	5,000	12.0063	5,000	12.0063	60,032
2017-08-08	NHS	OREILLY THOMAS P	5,000	12.1214	5,000	12.1214	60,607
2017-08-07	NHS	OREILLY THOMAS P	4,000	12.1353	4,000	12.1353	48,541
2016-12-23	NHS	OREILLY THOMAS P	5,814	11.6028	5,814	11.6028	67,459
2016-12-22	NHS	OREILLY THOMAS P	4,186	11.6130	4,186	11.6130	48,612
2016-04-04	NHS	OREILLY THOMAS P	11,913	10.4185	11,913	10.4185	124,116
2016-04-01	NHS	OREILLY THOMAS P	18,087	10.5273	18,087	10.5273	190,407

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Trading History

This table shows the complete list of insider trades made by Thomas P Oreilly as disclosed to the Securities Exchange Commission (SEC).